+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hormonal Contraceptives Market by Product, Hormones, Age Group End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • ID: 5578242
  • Report
  • March 2022
  • Region: Global
  • 225 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Ansell LTD.
  • Bayer AG
  • Female Health Company
  • Johnson & Johnson
  • Mayer Laboratories
  • Merck & Co., Inc.
The global hormonal contraceptive market was valued at $ 15,026.23 million in 2020, and is projected to reach $ 20,672.64 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.

Hormonal contraceptives are birth control methods, which act on the endocrine system. These methods include use of hormones that are produced normally by women, such as estrogen and progesterone to prevent ovulation and in turn pregnancy. However, they do not provide protection against HIV or other sexually transmitted infections. There are two types of hormonal contraceptives available in the market, namely, progestin-only contraceptive and combination hormonal contraceptive. Hormonal contraception acts on the endocrine system to prevent unwanted pregnancy. Synthetic forms of naturally occurring hormones such as progestin and estrogen are used to prevent ovulation and avoid fertilization. These forms of birth control methods also change the environment of uterus, making it unfavorable for fertilization. They are available in a variety of forms such as patches, pill, injection, and rings, which are safe and reliable forms of hormonal contraceptives to prevent pregnancy.

Major factors that drive growth of the global hormonal contraceptive market include rise in focus toward family planning, health issues associated with teenage pregnancies, increase in awareness regarding modern contraception methods, and rise in use of oral pills as a key method to prevent unplanned pregnancy are expected to drive the market growth. In addition, advancements in hormonal contraception with better efficacy and fewer side effects propel the market growth. However, availability of alternate contraceptive methods, health risks associated with use of contraceptives, and lack of social acceptance restricts the market growth.

The global hormonal contraceptive market is segmented on the basis of product, hormone, age group, end user, and region. By product, the market is divided into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal rings, and transdermal patches. On the basis of hormones, it is divided into progestin-only contraceptive and combined hormonal contraceptive. On the basis of age group, it is divided into 15–24 years, 25–34 years, 35–44 years, and above 44 years. By end user, it is divided into hospitals, household, and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA).

The major companies profiled in the report include the Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell LTD., Mayer Laboratories, Merck & Co., Inc., and Church & Dwight, Co., Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis of the current market trends from 2020 to 2023to identify the prevailing opportunities
  • Market estimations are based on comprehensive analysis of the key developments in the industry
  • The global market is comprehensively analyzed with respect to product, hormone type, age group, end user, and region
  • In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market

KEY MARKET SEGMENTS


By Product

  • Oral Contraceptive Pills
  • Injectable Birth Control
  • Emergency Contraceptive Pills
  • Vaginal Rings
  • Transdermal Patches

By Hormones

  • Progestin-only Contraceptive
  • Combined Hormonal Contraceptive

By End User

  • Hospitals
  • Household
  • Clinics

By End User

  • 15–24 Years
  • 25–34 Years
  • 35–44 Years
  • Above 44 Years

By Region

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY PLAYERS

  • the Female Health Company
  • Teva Pharmaceutical Industries Limited
  • Bayer AG, Pfizer, Inc
  • Mylan NV
  • Johnson & Johnson
  • Ansell LTD
  • Mayer Laboratories
  • Merck & Co, Inc,
  • Church & Dwight, Co, Inc
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Ansell LTD.
  • Bayer AG
  • Female Health Company
  • Johnson & Johnson
  • Mayer Laboratories
  • Merck & Co., Inc.

Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis
Chapter 4: Hormonal Contraceptives Market, by Product Type
4.1. Market Overview
4.1.1Market Size and Forecast, by Product Type
4.2. Oral Contraceptive Pills
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.3. Injectable Birth Control
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
4.4. Emergency Contraceptive Pills
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Share Analysis, by Country
4.5. Vaginal Rings
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Share Analysis, by Country
4.6. Transdermal Patches
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Share Analysis, by Country
Chapter 5: Hormonal Contraceptives Market, by Hormone
5.1. Market Overview
5.1.1Market Size and Forecast, by Hormone
5.2. Progestin Only Contraceptive
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Share Analysis, by Country
5.3. Combined Hormonal Contraceptive
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, by Region
5.3.3. Market Share Analysis, by Country
Chapter 6: Hormonal Contraceptives Market, by Age Group
6.1. Market Overview
6.1.1Market Size and Forecast, by Age Group
6.2.15 to 24 Years
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, by Region
6.2.3. Market Share Analysis, by Country
6.3.25 to 34 Years
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, by Region
6.3.3. Market Share Analysis, by Country
6.4.35 to 44 Years
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, by Region
6.4.3. Market Share Analysis, by Country
6.5. Above 44 Years
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, by Region
6.5.3. Market Share Analysis, by Country
Chapter 7: Hormonal Contraceptives Market, by End-user
7.1. Market Overview
7.1.1Market Size and Forecast, by End-user
7.2. Hospitals
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, by Region
7.2.3. Market Share Analysis, by Country
7.3. Household
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, by Region
7.3.3. Market Share Analysis, by Country
7.4. Clinics
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, by Region
7.4.3. Market Share Analysis, by Country
Chapter 8: Hormonal Contraceptives Market, by Region
8.1. Market Overview
8.1.1Market Size and Forecast, by Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, by Product Type
8.2.3. Market Size and Forecast, by Hormone
8.2.4. Market Size and Forecast, by Age Group
8.2.5. Market Size and Forecast, by End-user
8.2.6. Market Size and Forecast, by Country
8.2.7. U. S. Hormonal Contraceptives Market
8.2.7.1. Market Size and Forecast, by Product Type
8.2.7.2. Market Size and Forecast, by Hormone
8.2.7.3. Market Size and Forecast, by Age Group
8.2.7.4. Market Size and Forecast, by End-user
8.2.8. Canada Hormonal Contraceptives Market
8.2.8.1. Market Size and Forecast, by Product Type
8.2.8.2. Market Size and Forecast, by Hormone
8.2.8.3. Market Size and Forecast, by Age Group
8.2.8.4. Market Size and Forecast, by End-user
8.2.9. Mexico Hormonal Contraceptives Market
8.2.9.1. Market Size and Forecast, by Product Type
8.2.9.2. Market Size and Forecast, by Hormone
8.2.9.3. Market Size and Forecast, by Age Group
8.2.9.4. Market Size and Forecast, by End-user
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, by Product Type
8.3.3. Market Size and Forecast, by Hormone
8.3.4. Market Size and Forecast, by Age Group
8.3.5. Market Size and Forecast, by End-user
8.3.6. Market Size and Forecast, by Country
8.3.7. Germany Hormonal Contraceptives Market
8.3.7.1. Market Size and Forecast, by Product Type
8.3.7.2. Market Size and Forecast, by Hormone
8.3.7.3. Market Size and Forecast, by Age Group
8.3.7.4. Market Size and Forecast, by End-user
8.3.8. France Hormonal Contraceptives Market
8.3.8.1. Market Size and Forecast, by Product Type
8.3.8.2. Market Size and Forecast, by Hormone
8.3.8.3. Market Size and Forecast, by Age Group
8.3.8.4. Market Size and Forecast, by End-user
8.3.9. UK Hormonal Contraceptives Market
8.3.9.1. Market Size and Forecast, by Product Type
8.3.9.2. Market Size and Forecast, by Hormone
8.3.9.3. Market Size and Forecast, by Age Group
8.3.9.4. Market Size and Forecast, by End-user
8.3.10. Italy Hormonal Contraceptives Market
8.3.10.1. Market Size and Forecast, by Product Type
8.3.10.2. Market Size and Forecast, by Hormone
8.3.10.3. Market Size and Forecast, by Age Group
8.3.10.4. Market Size and Forecast, by End-user
8.3.11. Spain Hormonal Contraceptives Market
8.3.11.1. Market Size and Forecast, by Product Type
8.3.11.2. Market Size and Forecast, by Hormone
8.3.11.3. Market Size and Forecast, by Age Group
8.3.11.4. Market Size and Forecast, by End-user
8.3.12. Rest of Europe Hormonal Contraceptives Market
8.3.12.1. Market Size and Forecast, by Product Type
8.3.12.2. Market Size and Forecast, by Hormone
8.3.12.3. Market Size and Forecast, by Age Group
8.3.12.4. Market Size and Forecast, by End-user
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, by Product Type
8.4.3. Market Size and Forecast, by Hormone
8.4.4. Market Size and Forecast, by Age Group
8.4.5. Market Size and Forecast, by End-user
8.4.6. Market Size and Forecast, by Country
8.4.7. Japan Hormonal Contraceptives Market
8.4.7.1. Market Size and Forecast, by Product Type
8.4.7.2. Market Size and Forecast, by Hormone
8.4.7.3. Market Size and Forecast, by Age Group
8.4.7.4. Market Size and Forecast, by End-user
8.4.8. China Hormonal Contraceptives Market
8.4.8.1. Market Size and Forecast, by Product Type
8.4.8.2. Market Size and Forecast, by Hormone
8.4.8.3. Market Size and Forecast, by Age Group
8.4.8.4. Market Size and Forecast, by End-user
8.4.9. Australia Hormonal Contraceptives Market
8.4.9.1. Market Size and Forecast, by Product Type
8.4.9.2. Market Size and Forecast, by Hormone
8.4.9.3. Market Size and Forecast, by Age Group
8.4.9.4. Market Size and Forecast, by End-user
8.4.10. India Hormonal Contraceptives Market
8.4.10.1. Market Size and Forecast, by Product Type
8.4.10.2. Market Size and Forecast, by Hormone
8.4.10.3. Market Size and Forecast, by Age Group
8.4.10.4. Market Size and Forecast, by End-user
8.4.11. South Korea Hormonal Contraceptives Market
8.4.11.1. Market Size and Forecast, by Product Type
8.4.11.2. Market Size and Forecast, by Hormone
8.4.11.3. Market Size and Forecast, by Age Group
8.4.11.4. Market Size and Forecast, by End-user
8.4.12. Rest of Asia-Pacific Hormonal Contraceptives Market
8.4.12.1. Market Size and Forecast, by Product Type
8.4.12.2. Market Size and Forecast, by Hormone
8.4.12.3. Market Size and Forecast, by Age Group
8.4.12.4. Market Size and Forecast, by End-user
8.5. Lamea
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, by Product Type
8.5.3. Market Size and Forecast, by Hormone
8.5.4. Market Size and Forecast, by Age Group
8.5.5. Market Size and Forecast, by End-user
8.5.6. Market Size and Forecast, by Country
8.5.7. Brazil Hormonal Contraceptives Market
8.5.7.1. Market Size and Forecast, by Product Type
8.5.7.2. Market Size and Forecast, by Hormone
8.5.7.3. Market Size and Forecast, by Age Group
8.5.7.4. Market Size and Forecast, by End-user
8.5.8. South Africa, Hormonal Contraceptives Market
8.5.8.1. Market Size and Forecast, by Product Type
8.5.8.2. Market Size and Forecast, by Hormone
8.5.8.3. Market Size and Forecast, by Age Group
8.5.8.4. Market Size and Forecast, by End-user
8.5.9. Saudi Arabia Hormonal Contraceptives Market
8.5.9.1. Market Size and Forecast, by Product Type
8.5.9.2. Market Size and Forecast, by Hormone
8.5.9.3. Market Size and Forecast, by Age Group
8.5.9.4. Market Size and Forecast, by End-user
8.5.10. Rest of LAMEA Hormonal Contraceptives Market
8.5.10.1. Market Size and Forecast, by Product Type
8.5.10.2. Market Size and Forecast, by Hormone
8.5.10.3. Market Size and Forecast, by Age Group
8.5.10.4. Market Size and Forecast, by End-user
Chapter 9: Company Profiles
9.1. Pfizer Inc.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Ansell Limited
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Bayer AG
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Church and Dwight Co. Inc
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Johnson and Johnson
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Mayer Laboratories Inc
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Merck and Co. Inc
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Mylan N. V
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Teva Pharmaceutical Industries Ltd
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. The Female Health Company
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
List of Tables
Table 1. Global Hormonal Contraceptives Market, by Product Type, 2020-2030 ($Million)
Table 2. Global Hormonal Contraceptives Market for Oral Contraceptive Pills, by Region, 2020-2030 ($Million)
Table 3. Global Hormonal Contraceptives Market for Injectable Birth Control, by Region, 2020-2030 ($Million)
Table 4. Global Hormonal Contraceptives Market for Emergency Contraceptive Pills, by Region, 2020-2030 ($Million)
Table 5. Global Hormonal Contraceptives Market for Vaginal Rings, by Region, 2020-2030 ($Million)
Table 6. Global Hormonal Contraceptives Market for Transdermal Patches, by Region, 2020-2030 ($Million)
Table 7. Global Hormonal Contraceptives Market, by Hormone, 2020-2030 ($Million)
Table 8. Global Hormonal Contraceptives Market for Progestin Only Contraceptive, by Region, 2020-2030 ($Million)
Table 9. Global Hormonal Contraceptives Market for Combined Hormonal Contraceptive, by Region, 2020-2030 ($Million)
Table 10. Global Hormonal Contraceptives Market, by Age Group, 2020-2030 ($Million)
Table 11. Global Hormonal Contraceptives Market for 15 to 24 Years, by Region, 2020-2030 ($Million)
Table 12. Global Hormonal Contraceptives Market for 25 to 34 Years, by Region, 2020-2030 ($Million)
Table 13. Global Hormonal Contraceptives Market for 35 to 44 Years, by Region, 2020-2030 ($Million)
Table 14. Global Hormonal Contraceptives Market for Above 44 Years, by Region, 2020-2030 ($Million)
Table 15. Global Hormonal Contraceptives Market, by End-user, 2020-2030 ($Million)
Table 16. Global Hormonal Contraceptives Market for Hospitals, by Region, 2020-2030 ($Million)
Table 17. Global Hormonal Contraceptives Market for Household, by Region, 2020-2030 ($Million)
Table 18. Global Hormonal Contraceptives Market for Clinics, by Region, 2020-2030 ($Million)
Table 19. Global Hormonal Contraceptives Market, by Region, 2020-2030 ($Million)
Table 20. North America Hormonal Contraceptives, by Region, 2020-2030 ($Million)
Table 21. North America Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 22. North America Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 23. North America Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 24. North America Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 25. U.S Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 26. U.S Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 27. U.S Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 28. U.S Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 29. Canada Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 30. Canada Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 31. Canada Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 32. Canada Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 33. Mexico Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 34. Mexico Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 35. Mexico Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 36. Mexico Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 37. Europe Hormonal Contraceptives, by Region, 2020-2030 ($Million)
Table 38. Europe Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 39. Europe Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 40. Europe Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 41. Europe Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 42. Germany Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 43. Germany Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 44. Germany Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 45. Germany Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 46. France Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 47. France Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 48. France Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 49. France Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 50. Uk Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 51. Uk Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 52. Uk Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 53. Uk Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 54. Italy Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 55. Italy Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 56. Italy Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 57. Italy Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 58. Spain Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 59. Spain Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 60. Spain Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 61. Spain Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 62. Rest of Europe Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 63. Rest of Europe Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 64. Rest of Europe Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 65. Rest of Europe Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 66. Asia-Pacific Hormonal Contraceptives, by Region, 2020-2030 ($Million)
Table 67. Asia-Pacific Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 68. Asia-Pacific Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 69. Asia-Pacific Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 70. Asia-Pacific Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 71. Japan Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 72. Japan Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 73. Japan Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 74. Japan Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 75. China Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 76. China Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 77. China Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 78. China Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 79. Australia Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 80. Australia Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 81. Australia Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 82. Australia Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 83. India Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 84. India Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 85. India Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 86. India Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 87. South Korea Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 88. South Korea Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 89. South Korea Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 90. South Korea Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 91. Rest of Asia-Pacific Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 92. Rest of Asia-Pacific Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 93. Rest of Asia-Pacific Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 94. Rest of Asia-Pacific Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 95. Lamea Hormonal Contraceptives, by Region, 2020-2030 ($Million)
Table 96. Lamea Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 97. Lamea Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 98. Lamea Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 99. Lamea Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 100. Brazil Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 101. Brazil Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 102. Brazil Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 103. Brazil Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 104. South Africa, Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 105. South Africa, Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 106. South Africa, Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 107. South Africa, Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 108. Saudi Arabia Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 109. Saudi Arabia Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 110. Saudi Arabia Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 111. Saudi Arabia Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 112. Rest of LAMEA Hormonal Contraceptives, by Product Type, 2020-2030 ($Million)
Table 113. Rest of LAMEA Hormonal Contraceptives, by Hormone, 2020-2030 ($Million)
Table 114. Rest of LAMEA Hormonal Contraceptives, by Age Group, 2020-2030 ($Million)
Table 115. Rest of LAMEA Hormonal Contraceptives, by End-user, 2020-2030 ($Million)
Table 116. Pfizer Inc. : Key Executives
Table 117. Pfizer Inc. : Company Snapshot
Table 118. Pfizer Inc. : Operating Segments
Table 119. Pfizer Inc. : Product Portfolio
Table 120. Pfizer Inc. : Key Strategic Moves and Developments
Table 121. Ansell Limited: Key Executives
Table 122. Ansell Limited: Company Snapshot
Table 123. Ansell Limited: Operating Segments
Table 124. Ansell Limited: Product Portfolio
Table 125. Ansell Limited: Key Strategic Moves and Developments
Table 126. Bayer Ag: Key Executives
Table 127. Bayer Ag: Company Snapshot
Table 128. Bayer Ag: Operating Segments
Table 129. Bayer Ag: Product Portfolio
Table 130. Bayer Ag: Key Strategic Moves and Developments
Table 131. Church and Dwight Co. Inc: Key Executives
Table 132. Church and Dwight Co. Inc: Company Snapshot
Table 133. Church and Dwight Co. Inc: Operating Segments
Table 134. Church and Dwight Co. Inc: Product Portfolio
Table 135. Church and Dwight Co. Inc: Key Strategic Moves and Developments
Table 136. Johnson and Johnson: Key Executives
Table 137. Johnson and Johnson: Company Snapshot
Table 138. Johnson and Johnson: Operating Segments
Table 139. Johnson and Johnson: Product Portfolio
Table 140. Johnson and Johnson: Key Strategic Moves and Developments
Table 141. Mayer Laboratories Inc: Key Executives
Table 142. Mayer Laboratories Inc: Company Snapshot
Table 143. Mayer Laboratories Inc: Operating Segments
Table 144. Mayer Laboratories Inc: Product Portfolio
Table 145. Mayer Laboratories Inc: Key Strategic Moves and Developments
Table 146. Merck and Co. Inc: Key Executives
Table 147. Merck and Co. Inc: Company Snapshot
Table 148. Merck and Co. Inc: Operating Segments
Table 149. Merck and Co. Inc: Product Portfolio
Table 150. Merck and Co. Inc: Key Strategic Moves and Developments
Table 151. Mylan N. V: Key Executives
Table 152. Mylan N. V: Company Snapshot
Table 153. Mylan N. V: Operating Segments
Table 154. Mylan N. V: Product Portfolio
Table 155. Mylan N. V: Key Strategic Moves and Developments
Table 156. Teva Pharmaceutical Industries Ltd: Key Executives
Table 157. Teva Pharmaceutical Industries Ltd: Company Snapshot
Table 158. Teva Pharmaceutical Industries Ltd: Operating Segments
Table 159. Teva Pharmaceutical Industries Ltd: Product Portfolio
Table 160. Teva Pharmaceutical Industries Ltd: Key Strategic Moves and Developments
Table 161. The Female Health Company: Key Executives
Table 162. The Female Health Company: Company Snapshot
Table 163. The Female Health Company: Operating Segments
Table 164. The Female Health Company: Product Portfolio
Table 165. The Female Health Company: Key Strategic Moves and Developments
List of Figures
Figure 1. Global Hormonal Contraceptives Market Segmentation
Figure 2. Global Hormonal Contraceptives Market
Figure 3. Segmentation Hormonal Contraceptives Market
Figure 4. Top Investment Pocket in Hormonal Contraceptives Market
Figure 5. Top Winning Strategies, 2019-2021*
Figure 6. Top Winning Strategies, by Development, 2019-2021(%)
Figure 7. Top Winning Strategies, by Company, 2019-2021*
Figure 8. Moderate Bargaining Power of Buyers
Figure 9. Moderate Bargaining Power of Suppliers
Figure 10. Moderate Threat of New Entrants
Figure 11. Low Threat of Substitution
Figure 12. High Competitive Rivalry
Figure 13. Top Player Positioning, 2020
Figure 14. Market Share Analysis, 2020
Figure 15. Restraints and Drivers: Hormonal Contraceptives Market
Figure 16. Hormonal Contraceptives Market Segmentation, by Product Type
Figure 17. Hormonal Contraceptives Market for Oral Contraceptive Pills, by Country, 2020-2030 ($ Million)
Figure 18. Hormonal Contraceptives Market for Injectable Birth Control, by Country, 2020-2030 ($ Million)
Figure 19. Hormonal Contraceptives Market for Emergency Contraceptive Pills, by Country, 2020-2030 ($ Million)
Figure 20. Hormonal Contraceptives Market for Vaginal Rings, by Country, 2020-2030 ($ Million)
Figure 21. Hormonal Contraceptives Market for Transdermal Patches, by Country, 2020-2030 ($ Million)
Figure 22. Hormonal Contraceptives Market Segmentation, by Hormone
Figure 23. Hormonal Contraceptives Market for Progestin Only Contraceptive, by Country, 2020-2030 ($ Million)
Figure 24. Hormonal Contraceptives Market for Combined Hormonal Contraceptive, by Country, 2020-2030 ($ Million)
Figure 25. Hormonal Contraceptives Market Segmentation, by Age Group
Figure 26. Hormonal Contraceptives Market for 15 to 24 Years, by Country, 2020-2030 ($ Million)
Figure 27. Hormonal Contraceptives Market for 25 to 34 Years, by Country, 2020-2030 ($ Million)
Figure 28. Hormonal Contraceptives Market for 35 to 44 Years, by Country, 2020-2030 ($ Million)
Figure 29. Hormonal Contraceptives Market for Above 44 Years, by Country, 2020-2030 ($ Million)
Figure 30. Hormonal Contraceptives Market Segmentation, by End-user
Figure 31. Hormonal Contraceptives Market for Hospitals, by Country, 2020-2030 ($ Million)
Figure 32. Hormonal Contraceptives Market for Household, by Country, 2020-2030 ($ Million)
Figure 33. Hormonal Contraceptives Market for Clinics, by Country, 2020-2030 ($ Million)
Figure 34. Pfizer Inc: Net Sales, 2018-2020 ($ Million)
Figure 35. Pfizer Inc: Revenue Share, by Segment, 2020 (%)
Figure 36. Pfizer Inc: Revenue Share, by Region, 2020 (%)
Figure 37. Ansell Limited: Net Sales, 2018-2020 ($ Million)
Figure 38. Ansell Limited: Revenue Share, by Segment, 2020 (%)
Figure 39. Ansell Limited: Revenue Share, by Region, 2020 (%)
Figure 40. Bayer Ag: Net Sales, 2018-2020 ($ Million)
Figure 41. Bayer Ag: Revenue Share, by Segment, 2020 (%)
Figure 42. Bayer Ag: Revenue Share, by Region, 2020 (%)
Figure 43. Church and Dwight Co. Inc: Net Sales, 2018-2020 ($ Million)
Figure 44. Church and Dwight Co. Inc: Revenue Share, by Segment, 2020 (%)
Figure 45. Church and Dwight Co. Inc: Revenue Share, by Region, 2020 (%)
Figure 46. Johnson and Johnson: Net Sales, 2018-2020 ($ Million)
Figure 47. Johnson and Johnson: Revenue Share, by Segment, 2020 (%)
Figure 48. Johnson and Johnson: Revenue Share, by Region, 2020 (%)
Figure 49. Mayer Laboratories Inc: Net Sales, 2018-2020 ($ Million)
Figure 50. Mayer Laboratories Inc: Revenue Share, by Segment, 2020 (%)
Figure 51. Mayer Laboratories Inc: Revenue Share, by Region, 2020 (%)
Figure 52. Merck and Co. Inc: Net Sales, 2018-2020 ($ Million)
Figure 53. Merck and Co. Inc: Revenue Share, by Segment, 2020 (%)
Figure 54. Merck and Co. Inc: Revenue Share, by Region, 2020 (%)
Figure 55. Mylan N. V: Net Sales, 2018-2020 ($ Million)
Figure 56. Mylan N. V: Revenue Share, by Segment, 2020 (%)
Figure 57. Mylan N. V: Revenue Share, by Region, 2020 (%)
Figure 58. Teva Pharmaceutical Industries Ltd: Net Sales, 2018-2020 ($ Million)
Figure 59. Teva Pharmaceutical Industries Ltd: Revenue Share, by Segment, 2020 (%)
Figure 60. Teva Pharmaceutical Industries Ltd: Revenue Share, by Region, 2020 (%)
Figure 61. The Female Health Company: Net Sales, 2018-2020 ($ Million)
Figure 62. The Female Health Company: Revenue Share, by Segment, 2020 (%)
Figure 63. The Female Health Company: Revenue Share, by Region, 2020 (%)
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Ansell LTD.
  • Bayer AG
  • Female Health Company
  • Johnson & Johnson
  • Mayer Laboratories
  • Merck & Co., Inc.
According to a new report titled, “hormonal contraceptive Market by product type, hormones, age group, end user: global opportunity analysis and industry forecast, 2021–2030,” The global hormonal contraceptives market size was valued at $ 15,026.23 million in 2020, and is projected to reach $ 20,672.64 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.

Hormonal contraception acts on the endocrine system to prevent unwanted pregnancy. Synthetic forms of naturally occurring hormones such as progestin and estrogen are used to prevent ovulation and avoid fertilization. These forms of birth control methods also change environment of the uterus, making it unfavorable for fertilization. Hormonal contraceptives are available in a variety of forms such as patches, pill, injection, and rings, which are safe and reliable forms of hormonal contraceptives to prevent pregnancy. Unplanned pregnancy is more prevalent among poor and low-income population. Contraceptive drugs & devices play a major role in prevention of unwanted pregnancy. Apart from government bodies, several nonprofit organizations impart education and awareness among the population.

Increase in focus toward family planning, health issues associated with teenage pregnancies, increase in awareness regarding modern contraception methods, and rise in use of oral pills as a key method to prevent unplanned pregnancy are expected to drive the market growth. In addition, advancements in hormonal contraception with better efficacy and fewer side effects further boosts the market growth. However, availability of alternate contraceptive methods, health risks associated with the use of contraceptives and lack of social acceptance restricts the market growth.

On the basis of type, the global hormonal contraceptives market is categorized into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal rings, and transdermal patches. Oral contraceptive pills are expected to dominate the market throughout the forecast period, owing to rise in focus on family planning among people and continuous support from the government. Furthermore, advancements in hormonal contraception such as advent of hormonal patches, implants, and other innovative drug-device combination products fuel the market growth. Moreover, several pharmaceutical companies focus on developing products for treatment of hormonal contraceptive, which is expected to drive growth of the market during the forecast period.

On the basis of hormones, the combined hormonal contraceptive segment accounted for a major share of the share in the global hormonal contraceptives market in 2020. This segment is expected to exhibit a prominent growth rate, owing to wide availability of combined hormonal contraceptive along with better efficiency to prevent pregnancy.

On the basis of age group, the 15–24 years segment accounted for a major share of the market share in the global Hormonal contraceptives market in 2020. This segment is expected to exhibit a prominent growth rate, owing due to the, Rise in concern about adolescent sexual activity specifically due to premarital and unplanned pregnancy often leads to premature discontinuation of schooling or abortion.

On the basis of end user, the Hormonal contraceptives market is classified as hospitals, household, and clinics. the household segment accounted for more than xx% of the global market share in 2020, and is expected to remain dominant during the forecast period, owing to the wide consumption of oral pills to avoid unplanned pregnancy. In addition, increase in use of contraceptives at home has improved health-related outcomes such as maternal and infant mortality

North America accounted for more than 41% of the global market share in 2020, and is expected to remain dominant throughout the forecast period. This was attributed to increase in awareness towards the benefits of using hormonal contraceptive, high prevalence of unwanted pregnancy, and favorable regulatory scenario. Asia-Pacific is projected to register the highest CAGR of 4.5% during the forecast period, owing due to presence of populace countries such as India and China where there is greater need to control the growing population offers a lucrative opportunity for the hormonal contraceptives market growth.

The major companies profiled in the report include the Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell LTD., Mayer Laboratories, Merck & Co., Inc., and Church & Dwight, Co., Inc.

Key Findings Of The Study


By Product type, the oral contraceptive pills segment is expected to experience rapid growth in the hormonal contraceptive market, and is projected to grow at a CAGR of 2.7% from 2021 to 2030
  • By hormones, combined hormonal contraceptive segment is projected to grow at a CAGR of 29% during the forecast period
  • By age group, 15-24 segment is expected to experience rapid growth in the hormonal contraceptives market, and is projected to grow at a CAGR of 37% from 2021 to 2030
By end user, household segment is projected to grow at a CAGR of 3.6% during the forecast period
Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 4.5% during the forecast period.
Note: Product cover images may vary from those shown
  • Female Health Company
  • Teva Pharmaceutical Industries Limited
  • Bayer AG
  • Pfizer, Inc.
  • Mylan N.V.
  • Johnson & Johnson
  • Ansell LTD.
  • Mayer Laboratories
  • Merck & Co., Inc.
  • Church & Dwight, Co., Inc.
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...